Johnson & Johnson Prostate Cancer Drug Impresses – Forbes

Johnson & Johnson Prostate Cancer Drug Impresses – Forbes.

A new study shows that Johnson & Johnson‘s prostate cancer pill Zytiga dramatically slows the progression of the disease in men who are not yet sick enough to start chemotherapy. Zytiga is already approved for use in patients after chemotherapy including the drug Taxotere has been given.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s